Navigation Links
Epigenetic control of cardiogenesis
Date:1/29/2013

This press release is available in German.

Many different tissues and organs form from pluripotent stem cells during embryonic development. To date it had been known that these processes are controlled by transcription factors for specific tissues. Scientists from the Max Planck Institute for Molecular Genetics in Berlin, in collaboration with colleagues at MIT and the Broad Institute in Boston, have now been able to demonstrate that RNA molecules, which do not act as templates for protein synthesis, participate in these processes as well. The scientists knocked down a gene for long non-coding RNA molecules (lncRNA) and thereby disrupted the development of the heart to an extent that was lethal to the embryos. Genesis of the ventral body wall was also impaired. It became apparent that the lncRNA participates in controlling transcription factors that themselves are responsible for controlling tissue- and organogenesis. The lncRNA itself thus acts as a modulating factor in these processes.

RNA molecules more than 300 nucleotides long and not exhibiting any protein-coding read frames are denoted as long non-coding RNA. They are known to interact with histone-modifying protein complexes that control the activation state of genes (activatable, active, or repressed), as well as influencing the level of their activity. This occurs, for example, through the transfer of methyl groups to histones, the DNA-packaging proteins. Modifications to the histones such as these can be copied during cell division and thus promulgate the activation state of genes from cell to cell across several stages of differentiation.

Max Planck scientists led by Bernhard Herrmann have proven for the first time that lncRNAs may also be indispensable for embryonic development. This was previously known primarily for transcription factors. They discovered an lncRNA, termed Fendrr, which is specifically formed in the progenitor cells of the heart and ventral body wall. After knocking down Fendrr in a mouse, the heart and ventral body wall were malformed, which was lethal to the embryos. The malformations first arose, however, several days after Fendrr had already been knocked down in the progenitor cells. In the case of transcription factors, the malformations appear, in contrast, after their inactivation for cells in which the gene is normally active.

This delay between the expression of the Fendrr-RNA and the appearance of the malformation can be explained by the specific effect of this new class of regulators. They influence the epigenetic control of target genes, including important transcription factors, namely by binding to histone-modifying protein complexes. Thus, they influence the fate of the descendants of cells in which they themselves were only briefly active.

The scientists now hope to locate further lncRNAs that control cardiogenesis and additional processes of embryonic development in mammals, and shed light on the mechanism of how they operate. Fendrr is probably only one of many lncRNAs that participate in epigenetic control of regulators for tissue- and organogenesis.


'/>"/>

Contact: Bernhard G. Herrmann
herrmann@molgen.mpg.de
49-308-413-1409
Max-Planck-Gesellschaft
Source:Eurekalert  

Related medicine news :

1. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
2. Epigenetics emerges powerfully as a clinical tool
3. New evidence for epigenetic effects of diet on healthy aging
4. Personal epigenetic signatures found consistent in prostate cancer patients metastases
5. Depo-Provera Birth Control Might Raise Breast Cancer Risk
6. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
7. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
8. How the brains daily clock controls mood: A new project
9. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
10. Control of gene expression: Histone occupancy in your genome
11. MSU plan would control deadly tsetse fly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Epigenetic control of cardiogenesis
(Date:2/9/2016)... Milwaukee, WI (PRWEB) , ... February 09, 2016 ... ... Bon-Ton, Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it ... Medical College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University ...
(Date:2/9/2016)... ... 09, 2016 , ... IsoComforter, Inc., one of the Nation’s ... designed, innovative shoulder wrap. The newly designed shoulder wrap has been specifically ... and shoulder to promote faster healing. It is highly recommended for arm or ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator ... preliminary data vendors in the latest KLAS report, Population Health Management 2015: How Far ... developing market for population health management (PHM). The latest KLAS Report, leveraging over ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), a ... financial results for the second quarter of fiscal 2016 (three months ... Financial Results for the Second Quarter of Fiscal ... Revenue for the second quarter of fiscal 2016 was $4.5 million, ... receipts from customers for the second quarter of fiscal 2016 were ...
(Date:2/9/2016)... February 9, 2016 QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QGEN ; Frankfurt ... 10x Genomics to develop and promote comprehensive solutions ... --> QIAGEN N.V. (NASDAQ: QGEN ...
Breaking Medicine Technology: